JP2017537100A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537100A5 JP2017537100A5 JP2017528520A JP2017528520A JP2017537100A5 JP 2017537100 A5 JP2017537100 A5 JP 2017537100A5 JP 2017528520 A JP2017528520 A JP 2017528520A JP 2017528520 A JP2017528520 A JP 2017528520A JP 2017537100 A5 JP2017537100 A5 JP 2017537100A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- optionally substituted
- independently selected
- oxo
- carbocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 356
- -1 amino, hydroxyl Chemical group 0.000 claims description 330
- 125000000623 heterocyclic group Chemical group 0.000 claims description 256
- 125000004043 oxo group Chemical group O=* 0.000 claims description 214
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 206
- 150000001875 compounds Chemical class 0.000 claims description 160
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 131
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 106
- 125000001072 heteroaryl group Chemical group 0.000 claims description 102
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 86
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 82
- 125000000304 alkynyl group Chemical group 0.000 claims description 74
- 229910052739 hydrogen Inorganic materials 0.000 claims description 66
- 125000003118 aryl group Chemical group 0.000 claims description 64
- 125000003342 alkenyl group Chemical group 0.000 claims description 59
- 125000003545 alkoxy group Chemical group 0.000 claims description 58
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 56
- 239000001257 hydrogen Substances 0.000 claims description 54
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 54
- 125000001424 substituent group Chemical group 0.000 claims description 47
- 239000000203 mixture Substances 0.000 claims description 45
- 229910052757 nitrogen Inorganic materials 0.000 claims description 45
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 44
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 44
- 150000003839 salts Chemical class 0.000 claims description 42
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 36
- 206010028980 Neoplasm Diseases 0.000 claims description 32
- 125000005936 piperidyl group Chemical group 0.000 claims description 32
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 32
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 32
- 125000002837 carbocyclic group Chemical group 0.000 claims description 31
- 125000003566 oxetanyl group Chemical group 0.000 claims description 30
- 239000003112 inhibitor Substances 0.000 claims description 29
- 201000011510 cancer Diseases 0.000 claims description 26
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims description 24
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 20
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 20
- 229940127089 cytotoxic agent Drugs 0.000 claims description 20
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 18
- 239000002254 cytotoxic agent Substances 0.000 claims description 18
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 18
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 18
- 125000004076 pyridyl group Chemical group 0.000 claims description 18
- 229910052799 carbon Inorganic materials 0.000 claims description 17
- OTTXCOAOKOEENK-UHFFFAOYSA-N 2,2-difluoroethenone Chemical group FC(F)=C=O OTTXCOAOKOEENK-UHFFFAOYSA-N 0.000 claims description 16
- YWPMKTWUFVOFPL-UHFFFAOYSA-N 3,4-dihydro-2h-isoquinolin-1-one Chemical compound C1=CC=C2C(=O)NCCC2=C1 YWPMKTWUFVOFPL-UHFFFAOYSA-N 0.000 claims description 16
- 241001465754 Metazoa Species 0.000 claims description 16
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 16
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 16
- 125000006255 cyclopropyl carbonyl group Chemical group [H]C1([H])C([H])([H])C1([H])C(*)=O 0.000 claims description 16
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 16
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims description 16
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 16
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 claims description 16
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 16
- 125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims description 16
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 claims description 16
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 15
- 125000006661 (C4-C6) heterocyclic group Chemical group 0.000 claims description 14
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 14
- 208000035475 disorder Diseases 0.000 claims description 14
- 230000003176 fibrotic effect Effects 0.000 claims description 14
- 206010039491 Sarcoma Diseases 0.000 claims description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 12
- 230000001404 mediated effect Effects 0.000 claims description 12
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 10
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 10
- 125000006299 oxetan-3-yl group Chemical group [H]C1([H])OC([H])([H])C1([H])* 0.000 claims description 10
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 claims description 8
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 8
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 8
- 206010016654 Fibrosis Diseases 0.000 claims description 8
- 208000019693 Lung disease Diseases 0.000 claims description 8
- PMDCZENCAXMSOU-UHFFFAOYSA-N N-ethylacetamide Chemical compound CCNC(C)=O PMDCZENCAXMSOU-UHFFFAOYSA-N 0.000 claims description 8
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 claims description 8
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 8
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims description 8
- 230000004761 fibrosis Effects 0.000 claims description 8
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 8
- 125000002971 oxazolyl group Chemical group 0.000 claims description 8
- 125000004351 phenylcyclohexyl group Chemical group C1(=CC=CC=C1)C1(CCCCC1)* 0.000 claims description 8
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 8
- 125000000335 thiazolyl group Chemical group 0.000 claims description 8
- 125000001425 triazolyl group Chemical group 0.000 claims description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 201000009030 Carcinoma Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 230000003511 endothelial effect Effects 0.000 claims description 6
- 239000005556 hormone Substances 0.000 claims description 6
- 229940088597 hormone Drugs 0.000 claims description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 6
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 5
- 230000004044 response Effects 0.000 claims description 5
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 4
- 125000006479 2-pyridyl methyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims description 4
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 claims description 4
- OFFFOVCCGHKJES-UHFFFAOYSA-N 4-methylthiadiazole Chemical compound CC1=CSN=N1 OFFFOVCCGHKJES-UHFFFAOYSA-N 0.000 claims description 4
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims description 4
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 4
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 4
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims description 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 4
- 201000004624 Dermatitis Diseases 0.000 claims description 4
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 4
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 4
- OHLUUHNLEMFGTQ-UHFFFAOYSA-N N-methylacetamide Chemical compound CNC(C)=O OHLUUHNLEMFGTQ-UHFFFAOYSA-N 0.000 claims description 4
- 201000004253 NUT midline carcinoma Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 4
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 4
- 229940123237 Taxane Drugs 0.000 claims description 4
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 4
- 206010057644 Testis cancer Diseases 0.000 claims description 4
- DGYIJVNZSDYBOE-UHFFFAOYSA-N [CH2]C1=CC=NC=C1 Chemical group [CH2]C1=CC=NC=C1 DGYIJVNZSDYBOE-UHFFFAOYSA-N 0.000 claims description 4
- 208000009956 adenocarcinoma Diseases 0.000 claims description 4
- 125000005605 benzo group Chemical group 0.000 claims description 4
- KVNRLNFWIYMESJ-UHFFFAOYSA-N butyronitrile Chemical compound CCCC#N KVNRLNFWIYMESJ-UHFFFAOYSA-N 0.000 claims description 4
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 229910052697 platinum Inorganic materials 0.000 claims description 4
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims description 4
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 claims description 4
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 4
- 208000010157 sclerosing cholangitis Diseases 0.000 claims description 4
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 4
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 4
- 201000003120 testicular cancer Diseases 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 claims description 3
- 239000005557 antagonist Substances 0.000 claims description 3
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 3
- 206010000830 Acute leukaemia Diseases 0.000 claims description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 208000026872 Addison Disease Diseases 0.000 claims description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 229940125431 BRAF inhibitor Drugs 0.000 claims description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 2
- 208000009137 Behcet syndrome Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 2
- 201000009047 Chordoma Diseases 0.000 claims description 2
- 208000006332 Choriocarcinoma Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 208000009798 Craniopharyngioma Diseases 0.000 claims description 2
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 claims description 2
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 2
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 2
- 208000007465 Giant cell arteritis Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 201000005569 Gout Diseases 0.000 claims description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 2
- 206010019668 Hepatic fibrosis Diseases 0.000 claims description 2
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 208000011200 Kawasaki disease Diseases 0.000 claims description 2
- 208000002260 Keloid Diseases 0.000 claims description 2
- 102100034671 L-lactate dehydrogenase A chain Human genes 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- 108010088350 Lactate Dehydrogenase 5 Proteins 0.000 claims description 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 2
- 208000018142 Leiomyosarcoma Diseases 0.000 claims description 2
- 208000005777 Lupus Nephritis Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000007054 Medullary Carcinoma Diseases 0.000 claims description 2
- 208000000172 Medulloblastoma Diseases 0.000 claims description 2
- 206010027406 Mesothelioma Diseases 0.000 claims description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 101100523539 Mus musculus Raf1 gene Proteins 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 206010028594 Myocardial fibrosis Diseases 0.000 claims description 2
- 208000009525 Myocarditis Diseases 0.000 claims description 2
- 201000002481 Myositis Diseases 0.000 claims description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 208000035327 Oestrogen receptor positive breast cancer Diseases 0.000 claims description 2
- 201000010133 Oligodendroglioma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 239000012828 PI3K inhibitor Substances 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims description 2
- 108091000080 Phosphotransferase Proteins 0.000 claims description 2
- 208000007641 Pinealoma Diseases 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 206010035742 Pneumonitis Diseases 0.000 claims description 2
- 208000008601 Polycythemia Diseases 0.000 claims description 2
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 2
- 206010036805 Progressive massive fibrosis Diseases 0.000 claims description 2
- 229940079156 Proteasome inhibitor Drugs 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 201000000582 Retinoblastoma Diseases 0.000 claims description 2
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 claims description 2
- 206010039705 Scleritis Diseases 0.000 claims description 2
- 201000010208 Seminoma Diseases 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 206010040070 Septic Shock Diseases 0.000 claims description 2
- 201000010001 Silicosis Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 2
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 208000001106 Takayasu Arteritis Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 claims description 2
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 claims description 2
- 206010044248 Toxic shock syndrome Diseases 0.000 claims description 2
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 206010046851 Uveitis Diseases 0.000 claims description 2
- 206010053648 Vascular occlusion Diseases 0.000 claims description 2
- 206010047115 Vasculitis Diseases 0.000 claims description 2
- 208000014070 Vestibular schwannoma Diseases 0.000 claims description 2
- 206010047642 Vitiligo Diseases 0.000 claims description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 2
- 208000008383 Wilms tumor Diseases 0.000 claims description 2
- 230000001594 aberrant effect Effects 0.000 claims description 2
- 208000004064 acoustic neuroma Diseases 0.000 claims description 2
- 201000011186 acute T cell leukemia Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 229940100198 alkylating agent Drugs 0.000 claims description 2
- 239000002168 alkylating agent Substances 0.000 claims description 2
- 230000000340 anti-metabolite Effects 0.000 claims description 2
- 229940044684 anti-microtubule agent Drugs 0.000 claims description 2
- 229940100197 antimetabolite Drugs 0.000 claims description 2
- 239000002256 antimetabolite Substances 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 230000006907 apoptotic process Effects 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 208000019748 bullous skin disease Diseases 0.000 claims description 2
- 230000022131 cell cycle Effects 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 208000024207 chronic leukemia Diseases 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 2
- 229960003668 docetaxel Drugs 0.000 claims description 2
- 206010014599 encephalitis Diseases 0.000 claims description 2
- 208000010932 epithelial neoplasm Diseases 0.000 claims description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical group C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 2
- 210000003743 erythrocyte Anatomy 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 201000007281 estrogen-receptor positive breast cancer Diseases 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 230000001605 fetal effect Effects 0.000 claims description 2
- 201000003444 follicular lymphoma Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 210000004602 germ cell Anatomy 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 208000002409 gliosarcoma Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 208000025750 heavy chain disease Diseases 0.000 claims description 2
- 201000002222 hemangioblastoma Diseases 0.000 claims description 2
- 230000002440 hepatic effect Effects 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 210000003494 hepatocyte Anatomy 0.000 claims description 2
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims description 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims description 2
- 239000002955 immunomodulating agent Substances 0.000 claims description 2
- 208000033065 inborn errors of immunity Diseases 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 210000001117 keloid Anatomy 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 2
- 206010024627 liposarcoma Diseases 0.000 claims description 2
- 230000001926 lymphatic effect Effects 0.000 claims description 2
- 208000003747 lymphoid leukemia Diseases 0.000 claims description 2
- 201000000564 macroglobulinemia Diseases 0.000 claims description 2
- 230000036210 malignancy Effects 0.000 claims description 2
- 210000001370 mediastinum Anatomy 0.000 claims description 2
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 claims description 2
- 206010027191 meningioma Diseases 0.000 claims description 2
- 230000004060 metabolic process Effects 0.000 claims description 2
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 206010028537 myelofibrosis Diseases 0.000 claims description 2
- 208000025113 myeloid leukemia Diseases 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 201000008383 nephritis Diseases 0.000 claims description 2
- 201000008026 nephroblastoma Diseases 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 201000004071 non-specific interstitial pneumonia Diseases 0.000 claims description 2
- 230000000414 obstructive effect Effects 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 125000003551 oxepanyl group Chemical group 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- 208000004019 papillary adenocarcinoma Diseases 0.000 claims description 2
- 201000010198 papillary carcinoma Diseases 0.000 claims description 2
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims description 2
- 102000020233 phosphotransferase Human genes 0.000 claims description 2
- 208000024724 pineal body neoplasm Diseases 0.000 claims description 2
- 230000001817 pituitary effect Effects 0.000 claims description 2
- 201000006292 polyarteritis nodosa Diseases 0.000 claims description 2
- 208000028529 primary immunodeficiency disease Diseases 0.000 claims description 2
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims description 2
- 230000000069 prophylactic effect Effects 0.000 claims description 2
- 239000003207 proteasome inhibitor Substances 0.000 claims description 2
- 150000003254 radicals Chemical class 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 201000002793 renal fibrosis Diseases 0.000 claims description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 claims description 2
- 230000019491 signal transduction Effects 0.000 claims description 2
- 230000011664 signaling Effects 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 210000004243 sweat Anatomy 0.000 claims description 2
- 201000008753 synovium neoplasm Diseases 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- 206010043207 temporal arteritis Diseases 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 206010043778 thyroiditis Diseases 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 208000021331 vascular occlusion disease Diseases 0.000 claims description 2
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical group CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims description 2
- 229960003862 vemurafenib Drugs 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 99
- 125000006706 (C3-C6) carbocyclyl group Chemical group 0.000 claims 6
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 4
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 3
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 2
- 229940122558 EGFR antagonist Drugs 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 229940093499 ethyl acetate Drugs 0.000 claims 1
- 235000019439 ethyl acetate Nutrition 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 claims 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 0 CC(N(C1)*c2c1c(Nc(cc1)ccc1-c1cccnc1C)n[n]2C)=O Chemical compound CC(N(C1)*c2c1c(Nc(cc1)ccc1-c1cccnc1C)n[n]2C)=O 0.000 description 104
- 125000005843 halogen group Chemical group 0.000 description 101
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- DGHJKOUXAHNRAP-UHFFFAOYSA-N 4-methyloxadiazole Chemical compound CC1=CON=N1 DGHJKOUXAHNRAP-UHFFFAOYSA-N 0.000 description 2
- LJPCNSSTRWGCMZ-YFKPBYRVSA-N C[C@@H]1COCC1 Chemical compound C[C@@H]1COCC1 LJPCNSSTRWGCMZ-YFKPBYRVSA-N 0.000 description 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- OSFVDNCNHWEOKC-GHRIWEEISA-N C/C(/c(cc1C(CC#N)C2)ccc1N2c1n[n](C2COCC2)c(CC2)c1CN2C(C)=O)=C\NC Chemical compound C/C(/c(cc1C(CC#N)C2)ccc1N2c1n[n](C2COCC2)c(CC2)c1CN2C(C)=O)=C\NC OSFVDNCNHWEOKC-GHRIWEEISA-N 0.000 description 1
- JMKKEJMTPPICOA-FWWKRHBFSA-N CC(/C=C(/c(cc1)cc2c1N(C)CCC2)\NC)=N Chemical compound CC(/C=C(/c(cc1)cc2c1N(C)CCC2)\NC)=N JMKKEJMTPPICOA-FWWKRHBFSA-N 0.000 description 1
- PRLAZICSKJHWGO-UHFFFAOYSA-N CC(C)CN(CC1)c(cc2)c1c(C)c2-c1c[n](C)nc1 Chemical compound CC(C)CN(CC1)c(cc2)c1c(C)c2-c1c[n](C)nc1 PRLAZICSKJHWGO-UHFFFAOYSA-N 0.000 description 1
- MASSWOMVPSTTLQ-WZQAJMDKSA-N CC(C)CN/C=C(\C=N)/c(cc1)ccc1Nc1n[n](C)c(CC2)c1CN2C(C)=O Chemical compound CC(C)CN/C=C(\C=N)/c(cc1)ccc1Nc1n[n](C)c(CC2)c1CN2C(C)=O MASSWOMVPSTTLQ-WZQAJMDKSA-N 0.000 description 1
- LYZIQOQONJWUCM-UHFFFAOYSA-N CC(C)Oc1ncccc1-c(cc1)ccc1Nc1n[n](C)c(CC2)c1CN2C(C)=O Chemical compound CC(C)Oc1ncccc1-c(cc1)ccc1Nc1n[n](C)c(CC2)c1CN2C(C)=O LYZIQOQONJWUCM-UHFFFAOYSA-N 0.000 description 1
- NCMLBFFUDRTDQF-UHFFFAOYSA-N CC(C1)CN(C)c2c1cc(-c1c[n](C)nc1)c(C#N)c2 Chemical compound CC(C1)CN(C)c2c1cc(-c1c[n](C)nc1)c(C#N)c2 NCMLBFFUDRTDQF-UHFFFAOYSA-N 0.000 description 1
- CIVLIHPKSFHIFY-UHFFFAOYSA-N CC(CN(CC1)CCC1[n](c(CC1)c2CN1C(C)=O)nc2N(CCCc1c2)c1cc(C(F)F)c2-c1c[n](C)nc1)(F)F Chemical compound CC(CN(CC1)CCC1[n](c(CC1)c2CN1C(C)=O)nc2N(CCCc1c2)c1cc(C(F)F)c2-c1c[n](C)nc1)(F)F CIVLIHPKSFHIFY-UHFFFAOYSA-N 0.000 description 1
- DJTQTXGNRGBCOD-UHFFFAOYSA-O CC(Cc1c2)CN(C(C(CN(CC3)C(NC)=O)=C3[NH2+]C3CCOCC3)=N)c1cc(C(F)F)c2-c1c[n](C)nc1 Chemical compound CC(Cc1c2)CN(C(C(CN(CC3)C(NC)=O)=C3[NH2+]C3CCOCC3)=N)c1cc(C(F)F)c2-c1c[n](C)nc1 DJTQTXGNRGBCOD-UHFFFAOYSA-O 0.000 description 1
- HAPPNYAXWQZRAX-UHFFFAOYSA-N CC(N(CC1)CC(C(N(CCCc2c3)c2cc(Cl)c3-c2c[n](C)nc2)=N)=C1NC1CCOCC1)=O Chemical compound CC(N(CC1)CC(C(N(CCCc2c3)c2cc(Cl)c3-c2c[n](C)nc2)=N)=C1NC1CCOCC1)=O HAPPNYAXWQZRAX-UHFFFAOYSA-N 0.000 description 1
- PTDAQHCADOZUPK-XKHUQQNRSA-O CC(N(CC1)CC(C(N(CCc2c3)c2ccc3/C(/C=[NH2+])=C/NC)=N)=C1NC1COC1)=O Chemical compound CC(N(CC1)CC(C(N(CCc2c3)c2ccc3/C(/C=[NH2+])=C/NC)=N)=C1NC1COC1)=O PTDAQHCADOZUPK-XKHUQQNRSA-O 0.000 description 1
- NYTUWAJIDVYHTR-UHFFFAOYSA-O CC(N(CC1)CC(C(N2c3cc(-c4c[n](C)nc4)cc(F)c3CC2)=N)=C1[NH2+]C1COCC1)=O Chemical compound CC(N(CC1)CC(C(N2c3cc(-c4c[n](C)nc4)cc(F)c3CC2)=N)=C1[NH2+]C1COCC1)=O NYTUWAJIDVYHTR-UHFFFAOYSA-O 0.000 description 1
- PJUDVGOSAFFXOW-UHFFFAOYSA-N CC(N(CC1)CC(C(Nc(cc2)ccc2-c2cc(C#N)cnc2)=N)=C1NC)=O Chemical compound CC(N(CC1)CC(C(Nc(cc2)ccc2-c2cc(C#N)cnc2)=N)=C1NC)=O PJUDVGOSAFFXOW-UHFFFAOYSA-N 0.000 description 1
- CDQRJTOIKYLWHC-UHFFFAOYSA-N CC(N(CC1)CC(C(Nc2cccc(-c3ccccn3)c2)=N)=C1NCC1CC1)=O Chemical compound CC(N(CC1)CC(C(Nc2cccc(-c3ccccn3)c2)=N)=C1NCC1CC1)=O CDQRJTOIKYLWHC-UHFFFAOYSA-N 0.000 description 1
- TXJYCXYYANUKRH-JFIRURCGSA-O CC(N(CC1)Cc2c1[n](C(CC1)CCC1(F)F)nc2N(CCCc1c2)c1cc(C(F)F)c2/C(/C=[NH2+])=C/NC)=O Chemical compound CC(N(CC1)Cc2c1[n](C(CC1)CCC1(F)F)nc2N(CCCc1c2)c1cc(C(F)F)c2/C(/C=[NH2+])=C/NC)=O TXJYCXYYANUKRH-JFIRURCGSA-O 0.000 description 1
- FOSCIUXFLQMEMH-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C(CC1)CCN1S(C)(=O)=O)nc2N(CCCc1c2)c1cc(C(F)(F)F)c2-c1c[n](C)nc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C(CC1)CCN1S(C)(=O)=O)nc2N(CCCc1c2)c1cc(C(F)(F)F)c2-c1c[n](C)nc1)=O FOSCIUXFLQMEMH-UHFFFAOYSA-N 0.000 description 1
- NOZQJGBVNUQNRB-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C(CCN1)CC1=O)nc2N(CCCc1c2)c1cc(C(F)F)c2-c1c[n](C)nc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C(CCN1)CC1=O)nc2N(CCCc1c2)c1cc(C(F)F)c2-c1c[n](C)nc1)=O NOZQJGBVNUQNRB-UHFFFAOYSA-N 0.000 description 1
- GSHNESMBKPVUKK-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2NC(CC1)=CC=C1c1c[n](CCNC)nc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2NC(CC1)=CC=C1c1c[n](CCNC)nc1)=O GSHNESMBKPVUKK-UHFFFAOYSA-N 0.000 description 1
- UECNFCVMDPPWBS-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c(cc1)ccc1C#N)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c(cc1)ccc1C#N)=O UECNFCVMDPPWBS-UHFFFAOYSA-N 0.000 description 1
- HWPRLXIVOJPGBP-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c(cc1)ccc1C(N(C)C)=O)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c(cc1)ccc1C(N(C)C)=O)=O HWPRLXIVOJPGBP-UHFFFAOYSA-N 0.000 description 1
- DRXZJLSQJJGIGZ-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c(cc1)ccc1C(N)=O)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c(cc1)ccc1C(N)=O)=O DRXZJLSQJJGIGZ-UHFFFAOYSA-N 0.000 description 1
- COVIVMNWGVXQCN-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c(cc1)ccc1C(N1CCOCC1)=O)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c(cc1)ccc1C(N1CCOCC1)=O)=O COVIVMNWGVXQCN-UHFFFAOYSA-N 0.000 description 1
- YFDFJEZICRPVLO-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c(cc1)ccc1Cl)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c(cc1)ccc1Cl)=O YFDFJEZICRPVLO-UHFFFAOYSA-N 0.000 description 1
- VKTQLUMELSJYIS-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c(cc1)ccc1F)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c(cc1)ccc1F)=O VKTQLUMELSJYIS-UHFFFAOYSA-N 0.000 description 1
- BNIJDOOXTWTXBB-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c(cc1)ccc1OC)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c(cc1)ccc1OC)=O BNIJDOOXTWTXBB-UHFFFAOYSA-N 0.000 description 1
- UFSZOWMSLVPJKA-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c(cc1)cnc1C#N)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c(cc1)cnc1C#N)=O UFSZOWMSLVPJKA-UHFFFAOYSA-N 0.000 description 1
- MHLYKCLCUQKRIA-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c(cc1)cnc1N)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c(cc1)cnc1N)=O MHLYKCLCUQKRIA-UHFFFAOYSA-N 0.000 description 1
- VGBJSBQUSBOSFQ-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c(cc1)cnc1O)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c(cc1)cnc1O)=O VGBJSBQUSBOSFQ-UHFFFAOYSA-N 0.000 description 1
- SBYNYIDQDRKIQN-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c(cc1F)ccc1F)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c(cc1F)ccc1F)=O SBYNYIDQDRKIQN-UHFFFAOYSA-N 0.000 description 1
- FSTSATFXXMERTN-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1c(C)ccnc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1c(C)ccnc1)=O FSTSATFXXMERTN-UHFFFAOYSA-N 0.000 description 1
- XKHATCVYWKUWMR-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1c(C)nc(C)cc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1c(C)nc(C)cc1)=O XKHATCVYWKUWMR-UHFFFAOYSA-N 0.000 description 1
- KQOCGYHXPOAIKM-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1c(CCCC2)[n]2nc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1c(CCCC2)[n]2nc1)=O KQOCGYHXPOAIKM-UHFFFAOYSA-N 0.000 description 1
- SSTRQKVGFZOZCS-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1c[n](C)nc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1c[n](C)nc1)=O SSTRQKVGFZOZCS-UHFFFAOYSA-N 0.000 description 1
- APFIMVUTPXXCGR-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1c[n](C)nc1C1CC1)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1c[n](C)nc1C1CC1)=O APFIMVUTPXXCGR-UHFFFAOYSA-N 0.000 description 1
- ZXSVBIKPEDHJHL-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1c[n](C2CC2)nc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1c[n](C2CC2)nc1)=O ZXSVBIKPEDHJHL-UHFFFAOYSA-N 0.000 description 1
- ILHQYEASSOOYPH-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1cc(C#N)ccc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1cc(C#N)ccc1)=O ILHQYEASSOOYPH-UHFFFAOYSA-N 0.000 description 1
- ORAGEWAFIXGRFQ-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1cc(C(F)(F)F)ccc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1cc(C(F)(F)F)ccc1)=O ORAGEWAFIXGRFQ-UHFFFAOYSA-N 0.000 description 1
- SAKMOVGKLKFYOY-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1cc(CO)ccc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1cc(CO)ccc1)=O SAKMOVGKLKFYOY-UHFFFAOYSA-N 0.000 description 1
- DIBRXRVMEOFHEB-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1cc(F)cc(F)c1)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1cc(F)cc(F)c1)=O DIBRXRVMEOFHEB-UHFFFAOYSA-N 0.000 description 1
- QIUPBVSHQMFACO-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1cc(F)ccc1F)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1cc(F)ccc1F)=O QIUPBVSHQMFACO-UHFFFAOYSA-N 0.000 description 1
- KPJLTNBOUVBDAV-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1ccc(C(F)(F)F)cc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1ccc(C(F)(F)F)cc1)=O KPJLTNBOUVBDAV-UHFFFAOYSA-N 0.000 description 1
- CFNPVNSKHBCVKD-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1ccc(C)cc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1ccc(C)cc1)=O CFNPVNSKHBCVKD-UHFFFAOYSA-N 0.000 description 1
- WXCLMMPHFVUIAO-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1ccc(C)nc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1ccc(C)nc1)=O WXCLMMPHFVUIAO-UHFFFAOYSA-N 0.000 description 1
- CQNCIJOYNCPJPT-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1ccc(CO)cc1)O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1ccc(CO)cc1)O CQNCIJOYNCPJPT-UHFFFAOYSA-N 0.000 description 1
- SARDUYMIJOPOTQ-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1cccc(Cl)c1)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1cccc(Cl)c1)=O SARDUYMIJOPOTQ-UHFFFAOYSA-N 0.000 description 1
- ITBMAEGNHCTABP-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1cccc(N(C)C)c1)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1cccc(N(C)C)c1)=O ITBMAEGNHCTABP-UHFFFAOYSA-N 0.000 description 1
- YHFIVAUGWSMFCX-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1cccc(NS(C)(=O)=O)c1)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1cccc(NS(C)(=O)=O)c1)=O YHFIVAUGWSMFCX-UHFFFAOYSA-N 0.000 description 1
- FRIOEGXJPBCNAX-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1cccc(OC)c1)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1cccc(OC)c1)=O FRIOEGXJPBCNAX-UHFFFAOYSA-N 0.000 description 1
- OPGVATQMBWJEIZ-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1ccccc1OC)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1ccccc1OC)=O OPGVATQMBWJEIZ-UHFFFAOYSA-N 0.000 description 1
- UGGSKEWBLNTYIP-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1ccncc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1ccncc1)=O UGGSKEWBLNTYIP-UHFFFAOYSA-N 0.000 description 1
- ZHECXPMTHGPGQQ-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1cncc(S=O)c1)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1cncc(S=O)c1)=O ZHECXPMTHGPGQQ-UHFFFAOYSA-N 0.000 description 1
- OIJFJYQRIPPLEI-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1cncnc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1cncnc1)=O OIJFJYQRIPPLEI-UHFFFAOYSA-N 0.000 description 1
- STCRPPIWTJYFNV-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1n[n](C)cc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2Nc(cc1)ccc1-c1n[n](C)cc1)=O STCRPPIWTJYFNV-UHFFFAOYSA-N 0.000 description 1
- XJBFFRZIFUFSCO-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1CCN(C)CC1)nc2N(CCCc1c2)c1cc(C(F)F)c2-c1c[n](C)nc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C1CCN(C)CC1)nc2N(CCCc1c2)c1cc(C(F)F)c2-c1c[n](C)nc1)=O XJBFFRZIFUFSCO-UHFFFAOYSA-N 0.000 description 1
- MVSOEOSCTVFUNY-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1CCN(CC(F)F)CC1)nc2N(CCCc1c2)c1cc(C(F)F)c2-c1c[n](C)nc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C1CCN(CC(F)F)CC1)nc2N(CCCc1c2)c1cc(C(F)F)c2-c1c[n](C)nc1)=O MVSOEOSCTVFUNY-UHFFFAOYSA-N 0.000 description 1
- RYSZMJJZGAVVTR-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2N(CCCc1c2)c1cc(Cl)c2-c1ccc(C(NC)=O)nc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2N(CCCc1c2)c1cc(Cl)c2-c1ccc(C(NC)=O)nc1)=O RYSZMJJZGAVVTR-UHFFFAOYSA-N 0.000 description 1
- UQBXFDFEKJCZNR-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2N1c(cc(c(-c2c[n](C)nc2)c2)C#N)c2N(C)CC1)=O Chemical compound CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2N1c(cc(c(-c2c[n](C)nc2)c2)C#N)c2N(C)CC1)=O UQBXFDFEKJCZNR-UHFFFAOYSA-N 0.000 description 1
- NRFLQCHTKOFVMD-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1COC1)nc2N(CCc1c2)c1ccc2-c1c[n](C)nc1C(F)(F)F)=O Chemical compound CC(N(CC1)Cc2c1[n](C1COC1)nc2N(CCc1c2)c1ccc2-c1c[n](C)nc1C(F)(F)F)=O NRFLQCHTKOFVMD-UHFFFAOYSA-N 0.000 description 1
- QHKVSIFGMSAWIN-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1COC1)nc2N1c(cccc2)c2OCC1)=O Chemical compound CC(N(CC1)Cc2c1[n](C1COC1)nc2N1c(cccc2)c2OCC1)=O QHKVSIFGMSAWIN-UHFFFAOYSA-N 0.000 description 1
- GUAPUOMXJMGULQ-QKMGMZOJSA-N CC(N(CC1)Cc2c1[n](C1COCC1)nc2N(CC1(CCC1)c1c2)c1ccc2/C(/C=N)=C/NC)=O Chemical compound CC(N(CC1)Cc2c1[n](C1COCC1)nc2N(CC1(CCC1)c1c2)c1ccc2/C(/C=N)=C/NC)=O GUAPUOMXJMGULQ-QKMGMZOJSA-N 0.000 description 1
- NIIYWMZVBGRPFQ-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1COCC1)nc2N(CCc1c2)c1cc(-c1c[n](C)nc1)c2C#N)=O Chemical compound CC(N(CC1)Cc2c1[n](C1COCC1)nc2N(CCc1c2)c1cc(-c1c[n](C)nc1)c2C#N)=O NIIYWMZVBGRPFQ-UHFFFAOYSA-N 0.000 description 1
- ZZJJNIBOIICGMV-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1COCC1)nc2N(CCc1c2)c1ccc2-c1c(C)[n](C)nc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C1COCC1)nc2N(CCc1c2)c1ccc2-c1c(C)[n](C)nc1)=O ZZJJNIBOIICGMV-UHFFFAOYSA-N 0.000 description 1
- VVKXKCAVGFHMJO-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1COCC1)nc2N(CCc1c2)c1ccc2-c1c[n](C)nc1C#N)=O Chemical compound CC(N(CC1)Cc2c1[n](C1COCC1)nc2N(CCc1c2)c1ccc2-c1c[n](C)nc1C#N)=O VVKXKCAVGFHMJO-UHFFFAOYSA-N 0.000 description 1
- VIIVDWHNVKREBX-VYRBHSGPSA-N CC(N(CC1)Cc2c1[n](C1COCC1)nc2N[C@H](C1)C=C(c2c[n](C)nc2)C(F)=C1F)=O Chemical compound CC(N(CC1)Cc2c1[n](C1COCC1)nc2N[C@H](C1)C=C(c2c[n](C)nc2)C(F)=C1F)=O VIIVDWHNVKREBX-VYRBHSGPSA-N 0.000 description 1
- XEIUTMNBFUKUEA-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1COCC1)nc2Nc(cc(cc1)-c2c[n](C)nc2)c1[I]=C)=N Chemical compound CC(N(CC1)Cc2c1[n](C1COCC1)nc2Nc(cc(cc1)-c2c[n](C)nc2)c1[I]=C)=N XEIUTMNBFUKUEA-UHFFFAOYSA-N 0.000 description 1
- ZNIQPKLUCOYTFF-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1COCC1)nc2Nc(cc1)ccc1-c1c[n](C)nc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C1COCC1)nc2Nc(cc1)ccc1-c1c[n](C)nc1)=O ZNIQPKLUCOYTFF-UHFFFAOYSA-N 0.000 description 1
- NJYJBDLOOBAKLR-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1COCC1)nc2Nc(ccc(-c1c[n](C)nc1)c1)c1Cl)=O Chemical compound CC(N(CC1)Cc2c1[n](C1COCC1)nc2Nc(ccc(-c1c[n](C)nc1)c1)c1Cl)=O NJYJBDLOOBAKLR-UHFFFAOYSA-N 0.000 description 1
- PQOUPUVPGGSLQQ-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1COCC1)nc2Nc1ccc(C2C=NN(C)C2C(F)(F)F)cc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C1COCC1)nc2Nc1ccc(C2C=NN(C)C2C(F)(F)F)cc1)=O PQOUPUVPGGSLQQ-UHFFFAOYSA-N 0.000 description 1
- NKXTWOBELGVLPJ-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](CC(CCN1)CC1=O)nc2N(CCCc1c2)c1cc(C(F)F)c2-c1c[n](C)nc1)=O Chemical compound CC(N(CC1)Cc2c1[n](CC(CCN1)CC1=O)nc2N(CCCc1c2)c1cc(C(F)F)c2-c1c[n](C)nc1)=O NKXTWOBELGVLPJ-UHFFFAOYSA-N 0.000 description 1
- MKHZYJVBJCVUJD-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](CC1CC1)nc2Nc1cc(-c2ccncc2)ccc1)=O Chemical compound CC(N(CC1)Cc2c1[n](CC1CC1)nc2Nc1cc(-c2ccncc2)ccc1)=O MKHZYJVBJCVUJD-UHFFFAOYSA-N 0.000 description 1
- WJCOZSIUTNNQCH-ZIGUYKLESA-N CC(N(CC1)Cc2c1[n](CCC(F)(F)F)nc2Nc(cc1)ccc1-c1c[n](CCC(N(CC2)Cc3c2[n](CCC(N)=O)nc3Nc(cc2)ccc2/C(/C=N)=C/NC)=O)nc1)=O Chemical compound CC(N(CC1)Cc2c1[n](CCC(F)(F)F)nc2Nc(cc1)ccc1-c1c[n](CCC(N(CC2)Cc3c2[n](CCC(N)=O)nc3Nc(cc2)ccc2/C(/C=N)=C/NC)=O)nc1)=O WJCOZSIUTNNQCH-ZIGUYKLESA-N 0.000 description 1
- QUDSANXOMKRWBR-FQEVSTJZSA-N CC(N(CC1)Cc2c1[n](CC[C@@H]1COCC1)nc2N(CCc1c2)c1ccc2-c1c(C)[n](C)nc1)=O Chemical compound CC(N(CC1)Cc2c1[n](CC[C@@H]1COCC1)nc2N(CCc1c2)c1ccc2-c1c(C)[n](C)nc1)=O QUDSANXOMKRWBR-FQEVSTJZSA-N 0.000 description 1
- BYSDTPTWZYDBDL-OYRHEFFESA-N CC(N(CC1)Cc2c1[n]([C@H](CC1)CC[C@H]1O)nc2N(CCCc1c2)c1cc(C(F)F)c2-c1c[n](C)nc1)=O Chemical compound CC(N(CC1)Cc2c1[n]([C@H](CC1)CC[C@H]1O)nc2N(CCCc1c2)c1cc(C(F)F)c2-c1c[n](C)nc1)=O BYSDTPTWZYDBDL-OYRHEFFESA-N 0.000 description 1
- JDCXRWQQMMOJEQ-UHFFFAOYSA-N CC(Nc(cc1)ncc1-c(cc1)ccc1Nc1n[n](C)c(CC2)c1CN2C(C)=O)=O Chemical compound CC(Nc(cc1)ncc1-c(cc1)ccc1Nc1n[n](C)c(CC2)c1CN2C(C)=O)=O JDCXRWQQMMOJEQ-UHFFFAOYSA-N 0.000 description 1
- RKBYTUZWJBPSDE-UHFFFAOYSA-N CC(Nc(cc1)ncc1-c(cc1CCC2)c(C(F)F)cc1N2c1n[n](C2CCOCC2)c(CC2)c1CN2C(NC)=O)=O Chemical compound CC(Nc(cc1)ncc1-c(cc1CCC2)c(C(F)F)cc1N2c1n[n](C2CCOCC2)c(CC2)c1CN2C(NC)=O)=O RKBYTUZWJBPSDE-UHFFFAOYSA-N 0.000 description 1
- GCCHDQDWCOCDLK-UHFFFAOYSA-N CC1(c(cc2)ccc2Nc2n[n](C)c(CC3)c2CN3C(C)=O)NNC=C1 Chemical compound CC1(c(cc2)ccc2Nc2n[n](C)c(CC3)c2CN3C(C)=O)NNC=C1 GCCHDQDWCOCDLK-UHFFFAOYSA-N 0.000 description 1
- GSDYNJRRFBBEJS-UHFFFAOYSA-N CC1=CCOC1 Chemical compound CC1=CCOC1 GSDYNJRRFBBEJS-UHFFFAOYSA-N 0.000 description 1
- KAJXBJOCILTJII-UHFFFAOYSA-N CC1c(cc(cc2)-c3c[n](C)nc3)c2N(C)CC1 Chemical compound CC1c(cc(cc2)-c3c[n](C)nc3)c2N(C)CC1 KAJXBJOCILTJII-UHFFFAOYSA-N 0.000 description 1
- OQRQSVFKODEYMA-UHFFFAOYSA-N CCC(CC)N(CCC1)c(cc2C(F)F)c1cc2-c(ccnc1)c1N Chemical compound CCC(CC)N(CCC1)c(cc2C(F)F)c1cc2-c(ccnc1)c1N OQRQSVFKODEYMA-UHFFFAOYSA-N 0.000 description 1
- KHXCSFOBXLYDGJ-UHFFFAOYSA-O CCC1c2cc(C(C=N)=C[NH2+]C)ccc2N(C)C1 Chemical compound CCC1c2cc(C(C=N)=C[NH2+]C)ccc2N(C)C1 KHXCSFOBXLYDGJ-UHFFFAOYSA-O 0.000 description 1
- YHRDDTJESSMWLA-JZQXYNAISA-O CCCC(C)N(CC[C@@H]1C)c2c1cc(/C(/C=[NH2+])=C/NC)c(C#N)c2 Chemical compound CCCC(C)N(CC[C@@H]1C)c2c1cc(/C(/C=[NH2+])=C/NC)c(C#N)c2 YHRDDTJESSMWLA-JZQXYNAISA-O 0.000 description 1
- PFODMDCSNDGMPE-UHFFFAOYSA-N CCCC(CC)N(CC1)c2c1c(Cl)cc(-c1c[n](C)nc1)c2 Chemical compound CCCC(CC)N(CC1)c2c1c(Cl)cc(-c1c[n](C)nc1)c2 PFODMDCSNDGMPE-UHFFFAOYSA-N 0.000 description 1
- FBKNOQMUWJSRPK-UHFFFAOYSA-N CCCC(CC)N(CCC1)c(cc2)c1cc2-c1c[n](C(F)[I]=C)nc1 Chemical compound CCCC(CC)N(CCC1)c(cc2)c1cc2-c1c[n](C(F)[I]=C)nc1 FBKNOQMUWJSRPK-UHFFFAOYSA-N 0.000 description 1
- XOWDMKGWQQKRDZ-UHFFFAOYSA-N CCCC(CC)N(CCC1)c2c1cc(-c1cnc(N(C)C)[s]1)c(C(F)F)c2 Chemical compound CCCC(CC)N(CCC1)c2c1cc(-c1cnc(N(C)C)[s]1)c(C(F)F)c2 XOWDMKGWQQKRDZ-UHFFFAOYSA-N 0.000 description 1
- VUOLINRXKDODNT-UHFFFAOYSA-N CCCCC(CC)N(CC1)c2c1ccc(C#N)c2 Chemical compound CCCCC(CC)N(CC1)c2c1ccc(C#N)c2 VUOLINRXKDODNT-UHFFFAOYSA-N 0.000 description 1
- LYSZWOOLLBURRQ-UHFFFAOYSA-N CCCCC(CCC)N(CCC1)c(cc2)c1cc2-c1c[n](C)c(C)n1 Chemical compound CCCCC(CCC)N(CCC1)c(cc2)c1cc2-c1c[n](C)c(C)n1 LYSZWOOLLBURRQ-UHFFFAOYSA-N 0.000 description 1
- CLBDSPYJYDXQGV-UHFFFAOYSA-N CCCCC(CCC)N(CCC1)c2c1cc(-c1c[n](C)nc1)c(OC(F)(F)F)c2 Chemical compound CCCCC(CCC)N(CCC1)c2c1cc(-c1c[n](C)nc1)c(OC(F)(F)F)c2 CLBDSPYJYDXQGV-UHFFFAOYSA-N 0.000 description 1
- UISBXVKXXGYEOR-UHFFFAOYSA-N CCCCC(CCC)N(CCC1)c2c1cc(-c1c[n](C)nc1)nc2 Chemical compound CCCCC(CCC)N(CCC1)c2c1cc(-c1c[n](C)nc1)nc2 UISBXVKXXGYEOR-UHFFFAOYSA-N 0.000 description 1
- ZAOSJQKDPIERFK-QSVWIEALSA-N CCCCC(CCC)N(CC[C@@H]1CO)c(cc2)c1cc2-c1c[n](C)nc1 Chemical compound CCCCC(CCC)N(CC[C@@H]1CO)c(cc2)c1cc2-c1c[n](C)nc1 ZAOSJQKDPIERFK-QSVWIEALSA-N 0.000 description 1
- AABQTXWBISAECL-UHFFFAOYSA-N CCCCCC(CC)N(CCC1C)c2c1cc(-c1c[n](C)nc1)c(C#N)c2 Chemical compound CCCCCC(CC)N(CCC1C)c2c1cc(-c1c[n](C)nc1)c(C#N)c2 AABQTXWBISAECL-UHFFFAOYSA-N 0.000 description 1
- KAGWUEGUSFLQBK-UHFFFAOYSA-N CCN(C)c(cc1)ccc1-c1c[n](C)nc1 Chemical compound CCN(C)c(cc1)ccc1-c1c[n](C)nc1 KAGWUEGUSFLQBK-UHFFFAOYSA-N 0.000 description 1
- VGZJQQKSDVFGFA-UHFFFAOYSA-N CC[n]1ncc(-c(cc2)ccc2Nc2n[n](C)c(CC3)c2CN3C(C)=O)c1 Chemical compound CC[n]1ncc(-c(cc2)ccc2Nc2n[n](C)c(CC3)c2CN3C(C)=O)c1 VGZJQQKSDVFGFA-UHFFFAOYSA-N 0.000 description 1
- LRLZXUXUQXYOOB-UHFFFAOYSA-N CN(CCC1)c(cc2)c1cc2-c1cc(C#N)cnc1 Chemical compound CN(CCC1)c(cc2)c1cc2-c1cc(C#N)cnc1 LRLZXUXUQXYOOB-UHFFFAOYSA-N 0.000 description 1
- KMXBOEUIAAJSLA-UHFFFAOYSA-N CN(CCC1)c(cc2)c1cc2-c1cncnc1 Chemical compound CN(CCC1)c(cc2)c1cc2-c1cncnc1 KMXBOEUIAAJSLA-UHFFFAOYSA-N 0.000 description 1
- AMDLFSPNCBSFLZ-UHFFFAOYSA-N CN(CCC1)c(cc2C#N)c1cc2-c1ccncn1 Chemical compound CN(CCC1)c(cc2C#N)c1cc2-c1ccncn1 AMDLFSPNCBSFLZ-UHFFFAOYSA-N 0.000 description 1
- MBWCZXOGYULJOO-UHFFFAOYSA-N CN(CCC1)c2c1c(Cl)ccc2 Chemical compound CN(CCC1)c2c1c(Cl)ccc2 MBWCZXOGYULJOO-UHFFFAOYSA-N 0.000 description 1
- UDEULHRWMVNDEF-UHFFFAOYSA-N CN(CCC1)c2c1cc(C1SC=NC1)cc2 Chemical compound CN(CCC1)c2c1cc(C1SC=NC1)cc2 UDEULHRWMVNDEF-UHFFFAOYSA-N 0.000 description 1
- ZCOWMMYJJXWULI-UHFFFAOYSA-N CN(CCCc1c2)c1ccc2-c(cc1)cnc1C#N Chemical compound CN(CCCc1c2)c1ccc2-c(cc1)cnc1C#N ZCOWMMYJJXWULI-UHFFFAOYSA-N 0.000 description 1
- DNIOPDVYJJBBBS-UHFFFAOYSA-N CN(CCc1c2)c1cc(C#N)c2-c1c[n](C)nc1 Chemical compound CN(CCc1c2)c1cc(C#N)c2-c1c[n](C)nc1 DNIOPDVYJJBBBS-UHFFFAOYSA-N 0.000 description 1
- RDKUCKKETDMFBU-UHFFFAOYSA-N CN(c1ccccc1)c(cc1)ccc1-c1c[n](C)nc1 Chemical compound CN(c1ccccc1)c(cc1)ccc1-c1c[n](C)nc1 RDKUCKKETDMFBU-UHFFFAOYSA-N 0.000 description 1
- AKUXPVUGTVAHCD-RMTVOBLGSA-N CN/C=C(\C=N)/c(cc1)cc2c1N(C)C[C@H]2CC#N Chemical compound CN/C=C(\C=N)/c(cc1)cc2c1N(C)C[C@H]2CC#N AKUXPVUGTVAHCD-RMTVOBLGSA-N 0.000 description 1
- YUBKNKQXHGLULJ-PDVFJIAZSA-N CN/C=C(\C=N)/c(cc1)ccc1N(C)c1ccccc1 Chemical compound CN/C=C(\C=N)/c(cc1)ccc1N(C)c1ccccc1 YUBKNKQXHGLULJ-PDVFJIAZSA-N 0.000 description 1
- UTRSDTNSYNOFHK-BXBRPASWSA-O CN/C=C(\C=[NH2+])/c(cc1)cc(C2)c1N(C)CC2C1CC1 Chemical compound CN/C=C(\C=[NH2+])/c(cc1)cc(C2)c1N(C)CC2C1CC1 UTRSDTNSYNOFHK-BXBRPASWSA-O 0.000 description 1
- XSWFYGFHEHETNV-VVJXHRSYSA-O CN/C=C(\C=[NH2+])/c(cc1)cc2c1N(C)CC(CC(F)F)C2 Chemical compound CN/C=C(\C=[NH2+])/c(cc1)cc2c1N(C)CC(CC(F)F)C2 XSWFYGFHEHETNV-VVJXHRSYSA-O 0.000 description 1
- PYTBFFZXPKUFHY-FMBUXQRRSA-O CN/C=C(\C=[NH2+])/c1ccc2N(C)CC(CO)Cc2c1 Chemical compound CN/C=C(\C=[NH2+])/c1ccc2N(C)CC(CO)Cc2c1 PYTBFFZXPKUFHY-FMBUXQRRSA-O 0.000 description 1
- QWVPFQJBXPZUSK-UHFFFAOYSA-N CNC(N(CC1)CC(C(N(CCC2)c3c2cc(-c2c[n](C)nc2)c(C(F)F)c3)=N)=C1NC(CC1)CCC1OC)=O Chemical compound CNC(N(CC1)CC(C(N(CCC2)c3c2cc(-c2c[n](C)nc2)c(C(F)F)c3)=N)=C1NC(CC1)CCC1OC)=O QWVPFQJBXPZUSK-UHFFFAOYSA-N 0.000 description 1
- WISNGFXEEMWAHJ-UHFFFAOYSA-N CNC(N(CC1)CC(C(N(CCC2)c3c2cc(-c2c[n](C)nc2)c(C(F)F)c3)=N)=C1Nc1cccnc1)=O Chemical compound CNC(N(CC1)CC(C(N(CCC2)c3c2cc(-c2c[n](C)nc2)c(C(F)F)c3)=N)=C1Nc1cccnc1)=O WISNGFXEEMWAHJ-UHFFFAOYSA-N 0.000 description 1
- HXEBYFYBKCPGQZ-UHFFFAOYSA-O CNC(N(CC1)CC(C(N(CCCc2c3)c2cc(Cl)c3-c2c[n](C)nc2)=N)=C1[NH2+]C1CCOCC1)=O Chemical compound CNC(N(CC1)CC(C(N(CCCc2c3)c2cc(Cl)c3-c2c[n](C)nc2)=N)=C1[NH2+]C1CCOCC1)=O HXEBYFYBKCPGQZ-UHFFFAOYSA-O 0.000 description 1
- NHPSOTYCPZNXSW-UHFFFAOYSA-O CNC(N(CC1)CC(C(N2C3C=C(C(F)(F)F)C(c4c[n](C)nc4)=CC3CCC2)=N)=C1[NH2+]C1CCOCC1)=O Chemical compound CNC(N(CC1)CC(C(N2C3C=C(C(F)(F)F)C(c4c[n](C)nc4)=CC3CCC2)=N)=C1[NH2+]C1CCOCC1)=O NHPSOTYCPZNXSW-UHFFFAOYSA-O 0.000 description 1
- OLCHZCYSJRUSRX-UHFFFAOYSA-N CNC(N(CC1)Cc2c1[n](-c1ccccc1)nc2N(CCCc1c2)c1cc(C(F)F)c2-c1c[n](C)nc1)=O Chemical compound CNC(N(CC1)Cc2c1[n](-c1ccccc1)nc2N(CCCc1c2)c1cc(C(F)F)c2-c1c[n](C)nc1)=O OLCHZCYSJRUSRX-UHFFFAOYSA-N 0.000 description 1
- NKBOSLMTOJMTLZ-UHFFFAOYSA-N CNC(N(CC1)Cc2c1[n](-c1ccncc1)nc2N(CCCc1c2)c1cc(C(F)F)c2-c1c[n](C)nc1)=O Chemical compound CNC(N(CC1)Cc2c1[n](-c1ccncc1)nc2N(CCCc1c2)c1cc(C(F)F)c2-c1c[n](C)nc1)=O NKBOSLMTOJMTLZ-UHFFFAOYSA-N 0.000 description 1
- DCYODTYUBWATHC-UHFFFAOYSA-N CNC(N(CC1)Cc2c1[n](C1CCCCC1)nc2N(CCC1)c2c1cc(-c1c[n](C)nc1)c(C(F)F)c2)=O Chemical compound CNC(N(CC1)Cc2c1[n](C1CCCCC1)nc2N(CCC1)c2c1cc(-c1c[n](C)nc1)c(C(F)F)c2)=O DCYODTYUBWATHC-UHFFFAOYSA-N 0.000 description 1
- BLKIJAZMPMNLOV-UHFFFAOYSA-N CNC(N(CC1)Cc2c1[n](C1CCOCC1)nc2N(CCCc1c2)c1cc(C1CC1)c2-c1c[n](C)nc1)=O Chemical compound CNC(N(CC1)Cc2c1[n](C1CCOCC1)nc2N(CCCc1c2)c1cc(C1CC1)c2-c1c[n](C)nc1)=O BLKIJAZMPMNLOV-UHFFFAOYSA-N 0.000 description 1
- JQDHNNIGFYFJHU-UHFFFAOYSA-N CNC(N(CC1)Cc2c1[n](C1CCOCC1)nc2N(CCCc1c2)c1cc(C=C)c2-c1c[n](C)nc1)=O Chemical compound CNC(N(CC1)Cc2c1[n](C1CCOCC1)nc2N(CCCc1c2)c1cc(C=C)c2-c1c[n](C)nc1)=O JQDHNNIGFYFJHU-UHFFFAOYSA-N 0.000 description 1
- VDEXIQHMSLVIIG-UHFFFAOYSA-N CNC(N(CC1)Cc2c1[n](C1CCOCC1)nc2N(CCCc1c2)c1cc(S(C)(=O)=O)c2-c1c[n](C)nc1)=O Chemical compound CNC(N(CC1)Cc2c1[n](C1CCOCC1)nc2N(CCCc1c2)c1cc(S(C)(=O)=O)c2-c1c[n](C)nc1)=O VDEXIQHMSLVIIG-UHFFFAOYSA-N 0.000 description 1
- GESFMFCLSDLZCV-UHFFFAOYSA-N CNC(N(CC1)Cc2c1[n](C1CCOCC1)nc2N1c(cc(c(-c2c[n](C)nc2)c2)C#N)c2N(C)CC1)=O Chemical compound CNC(N(CC1)Cc2c1[n](C1CCOCC1)nc2N1c(cc(c(-c2c[n](C)nc2)c2)C#N)c2N(C)CC1)=O GESFMFCLSDLZCV-UHFFFAOYSA-N 0.000 description 1
- QIVDEDWWJMXDJB-MXVIHJGJSA-N CNC(N(CC1)Cc2c1[n]([C@H](CC1)CC[C@@H]1N)nc2N(CCC1)c2c1cc(-c1c[n](C)nc1)c(C(F)F)c2)=O Chemical compound CNC(N(CC1)Cc2c1[n]([C@H](CC1)CC[C@@H]1N)nc2N(CCC1)c2c1cc(-c1c[n](C)nc1)c(C(F)F)c2)=O QIVDEDWWJMXDJB-MXVIHJGJSA-N 0.000 description 1
- NCMLBFFUDRTDQF-NSHDSACASA-N C[C@@H](C1)CN(C)c2c1cc(-c1c[n](C)nc1)c(C#N)c2 Chemical compound C[C@@H](C1)CN(C)c2c1cc(-c1c[n](C)nc1)c(C#N)c2 NCMLBFFUDRTDQF-NSHDSACASA-N 0.000 description 1
- YWKGZWFAUXSDJY-OXJNMPFZSA-N C[C@@H](C1)c2cc(-c3c[n](C)nc3)ccc2N1c1n[n]([C@H]2COCC2)c(CC2)c1CN2C(C)=O Chemical compound C[C@@H](C1)c2cc(-c3c[n](C)nc3)ccc2N1c1n[n]([C@H]2COCC2)c(CC2)c1CN2C(C)=O YWKGZWFAUXSDJY-OXJNMPFZSA-N 0.000 description 1
- KTZSWHMPAOVIBK-PROIXAHCSA-N C[C@@H](C1)c2cc(/C(/C=N)=C/NC)ccc2N1c1n[n]([C@@H]2COCC2)c(CC2)c1CN2C(C)=O Chemical compound C[C@@H](C1)c2cc(/C(/C=N)=C/NC)ccc2N1c1n[n]([C@@H]2COCC2)c(CC2)c1CN2C(C)=O KTZSWHMPAOVIBK-PROIXAHCSA-N 0.000 description 1
- JYXKEWDWKKISID-INIZCTEOSA-N C[C@@H](C1CC1)[n](c(CC1)c2CN1C(NC)=O)nc2N(CCC1)c2c1cc(-c1c[n](C)nc1)c(C(F)F)c2 Chemical compound C[C@@H](C1CC1)[n](c(CC1)c2CN1C(NC)=O)nc2N(CCC1)c2c1cc(-c1c[n](C)nc1)c(C(F)F)c2 JYXKEWDWKKISID-INIZCTEOSA-N 0.000 description 1
- DJTQTXGNRGBCOD-KRWDZBQOSA-N C[C@@H](Cc1c2)CN(C(C(CN(CC3)C(NC)=O)=C3NC3CCOCC3)=N)c1cc(C(F)F)c2-c1c[n](C)nc1 Chemical compound C[C@@H](Cc1c2)CN(C(C(CN(CC3)C(NC)=O)=C3NC3CCOCC3)=N)c1cc(C(F)F)c2-c1c[n](C)nc1 DJTQTXGNRGBCOD-KRWDZBQOSA-N 0.000 description 1
- KAJXBJOCILTJII-NSHDSACASA-N C[C@@H]1c(cc(cc2)-c3c[n](C)nc3)c2N(C)CC1 Chemical compound C[C@@H]1c(cc(cc2)-c3c[n](C)nc3)c2N(C)CC1 KAJXBJOCILTJII-NSHDSACASA-N 0.000 description 1
- MLRPMBYWAALRFR-GOSISDBHSA-N C[C@H](C1)N(C)c(cc(-c2c[n](C)nc2)c(NC)c2)c2N1c1n[n](C2CCOCC2)c(CC2)c1CN2C(C)=O Chemical compound C[C@H](C1)N(C)c(cc(-c2c[n](C)nc2)c(NC)c2)c2N1c1n[n](C2CCOCC2)c(CC2)c1CN2C(C)=O MLRPMBYWAALRFR-GOSISDBHSA-N 0.000 description 1
- KTZSWHMPAOVIBK-OXODIXQHSA-N C[C@H](C1)c(cc(cc2)/C(/C=N)=C/NC)c2N1c1n[n]([C@@H]2COCC2)c(CC2)c1CN2C(C)=O Chemical compound C[C@H](C1)c(cc(cc2)/C(/C=N)=C/NC)c2N1c1n[n]([C@@H]2COCC2)c(CC2)c1CN2C(C)=O KTZSWHMPAOVIBK-OXODIXQHSA-N 0.000 description 1
- YWKGZWFAUXSDJY-OXQOHEQNSA-N C[C@H](C1)c2cc(-c3c[n](C)nc3)ccc2N1c1n[n]([C@H]2COCC2)c(CC2)c1CN2C(C)=O Chemical compound C[C@H](C1)c2cc(-c3c[n](C)nc3)ccc2N1c1n[n]([C@H]2COCC2)c(CC2)c1CN2C(C)=O YWKGZWFAUXSDJY-OXQOHEQNSA-N 0.000 description 1
- YBDQLHBVNXARAU-ZCFIWIBFSA-N C[C@H]1OCCCC1 Chemical compound C[C@H]1OCCCC1 YBDQLHBVNXARAU-ZCFIWIBFSA-N 0.000 description 1
- JGXJVICBEGNSIF-SJQKCGLASA-O C[C@H]1c(cc(cc2)/C(/C=[NH2+])=C/NC)c2N(C)CC1 Chemical compound C[C@H]1c(cc(cc2)/C(/C=[NH2+])=C/NC)c2N(C)CC1 JGXJVICBEGNSIF-SJQKCGLASA-O 0.000 description 1
- FYMVTDZRRWWRBV-UHFFFAOYSA-N C[N+]1(CCC2(CC2)CC1)[O-] Chemical compound C[N+]1(CCC2(CC2)CC1)[O-] FYMVTDZRRWWRBV-UHFFFAOYSA-N 0.000 description 1
- HSZOMYJQTCPQFF-UHFFFAOYSA-N C[n](cc1)nc1-c(cc1)cc2c1N(C)CCC2 Chemical compound C[n](cc1)nc1-c(cc1)cc2c1N(C)CCC2 HSZOMYJQTCPQFF-UHFFFAOYSA-N 0.000 description 1
- HYRKQAWMRNJTNV-UHFFFAOYSA-N C[n]1nc(C(F)F)c(-c(cc2)cc3c2N(C)CCC3)c1 Chemical compound C[n]1nc(C(F)F)c(-c(cc2)cc3c2N(C)CCC3)c1 HYRKQAWMRNJTNV-UHFFFAOYSA-N 0.000 description 1
- YMTQPRIAAJEJJH-UHFFFAOYSA-N C[n]1ncc(-c(c(OC)c2)cc3c2N(C)CCC3)c1 Chemical compound C[n]1ncc(-c(c(OC)c2)cc3c2N(C)CCC3)c1 YMTQPRIAAJEJJH-UHFFFAOYSA-N 0.000 description 1
- QVTYVXATVZRULO-UHFFFAOYSA-N C[n]1ncc(-c(cc(CCCN2C)c2c2)c2C#N)c1 Chemical compound C[n]1ncc(-c(cc(CCCN2C)c2c2)c2C#N)c1 QVTYVXATVZRULO-UHFFFAOYSA-N 0.000 description 1
- VTYXZXKTLLVOSE-UHFFFAOYSA-N C[n]1ncc(-c(cc2)cc(C3)c2N(C)CC3c2ccccc2)c1 Chemical compound C[n]1ncc(-c(cc2)cc(C3)c2N(C)CC3c2ccccc2)c1 VTYXZXKTLLVOSE-UHFFFAOYSA-N 0.000 description 1
- CDPTWLTVTCIUCU-UHFFFAOYSA-N C[n]1ncc(-c(cc2)cc3c2N(C)CC(COC)C3)c1 Chemical compound C[n]1ncc(-c(cc2)cc3c2N(C)CC(COC)C3)c1 CDPTWLTVTCIUCU-UHFFFAOYSA-N 0.000 description 1
- PMARIRPNODGTDV-UHFFFAOYSA-N C[n]1ncc(-c(cc2)cc3c2N(C)CCC3CO)c1 Chemical compound C[n]1ncc(-c(cc2)cc3c2N(C)CCC3CO)c1 PMARIRPNODGTDV-UHFFFAOYSA-N 0.000 description 1
- TVRLTDQPAUCUOE-UHFFFAOYSA-N C[n]1ncc(-c(cc2)cc3c2N(C)CCN3)c1 Chemical compound C[n]1ncc(-c(cc2)cc3c2N(C)CCN3)c1 TVRLTDQPAUCUOE-UHFFFAOYSA-N 0.000 description 1
- QVFCQBWCSZMULB-UHFFFAOYSA-N Cc(cc(C(NC)=O)nc1)c1-c(c(C#N)c1)cc2c1N(C)CCC2 Chemical compound Cc(cc(C(NC)=O)nc1)c1-c(c(C#N)c1)cc2c1N(C)CCC2 QVFCQBWCSZMULB-UHFFFAOYSA-N 0.000 description 1
- AFZXPYWOBUSUHJ-UHFFFAOYSA-N Cc(cc(c(CCC1)c2)N1c1n[n](C3CCOCC3)c(CC3)c1CN3C(NC)=O)c2-c1c[n](C)nc1 Chemical compound Cc(cc(c(CCC1)c2)N1c1n[n](C3CCOCC3)c(CC3)c1CN3C(NC)=O)c2-c1c[n](C)nc1 AFZXPYWOBUSUHJ-UHFFFAOYSA-N 0.000 description 1
- KFVPUFFWZHPGKR-UHFFFAOYSA-N Cc1c(-c2c(C(F)F)cc3N(C)CCCc3c2)[s]c(C)n1 Chemical compound Cc1c(-c2c(C(F)F)cc3N(C)CCCc3c2)[s]c(C)n1 KFVPUFFWZHPGKR-UHFFFAOYSA-N 0.000 description 1
- IXRUIAJQIUHYEB-UHFFFAOYSA-N Cc1cc(-c(c(C#N)c2)cc3c2N(C)CCC3)cnc1C(NC)=O Chemical compound Cc1cc(-c(c(C#N)c2)cc3c2N(C)CCC3)cnc1C(NC)=O IXRUIAJQIUHYEB-UHFFFAOYSA-N 0.000 description 1
- TWJOIFSCBRNBBE-UHFFFAOYSA-N Cc1cc(-c(c(C(F)F)c2)cc3c2N(C)CCC3)n[n]1C Chemical compound Cc1cc(-c(c(C(F)F)c2)cc3c2N(C)CCC3)n[n]1C TWJOIFSCBRNBBE-UHFFFAOYSA-N 0.000 description 1
- DLJJEYCPQOXWES-UHFFFAOYSA-N Cc1cc(-c(cc(CCCN2C)c2c2)c2C#N)ncc1 Chemical compound Cc1cc(-c(cc(CCCN2C)c2c2)c2C#N)ncc1 DLJJEYCPQOXWES-UHFFFAOYSA-N 0.000 description 1
- CILODPACWHFOCO-UHFFFAOYSA-N Cc1cc(-c2c[n](C)nc2)cc(I)c1 Chemical compound Cc1cc(-c2c[n](C)nc2)cc(I)c1 CILODPACWHFOCO-UHFFFAOYSA-N 0.000 description 1
- LXTLBLFQNPYOTF-UHFFFAOYSA-N Cc1cc(N(C)CCC2)c2cc1-c1c[n](C)nc1 Chemical compound Cc1cc(N(C)CCC2)c2cc1-c1c[n](C)nc1 LXTLBLFQNPYOTF-UHFFFAOYSA-N 0.000 description 1
- ILGIZHJZQMOHKT-UHFFFAOYSA-N Cc1ccc(-c(c(C#N)c2)cc3c2N(C)CCC3)nc1 Chemical compound Cc1ccc(-c(c(C#N)c2)cc3c2N(C)CCC3)nc1 ILGIZHJZQMOHKT-UHFFFAOYSA-N 0.000 description 1
- WBFBGAIIYFQWBH-UHFFFAOYSA-N Cc1cnccc1-c(c(C#N)c1)cc2c1N(C)CCC2 Chemical compound Cc1cnccc1-c(c(C#N)c1)cc2c1N(C)CCC2 WBFBGAIIYFQWBH-UHFFFAOYSA-N 0.000 description 1
- CMVMLEAWGSGYEC-UHFFFAOYSA-N Cc1n[n](C)cc1-c(c(C#N)c1)cc2c1N(C)CCC2 Chemical compound Cc1n[n](C)cc1-c(c(C#N)c1)cc2c1N(C)CCC2 CMVMLEAWGSGYEC-UHFFFAOYSA-N 0.000 description 1
- MINYWMSCUCJKMH-UHFFFAOYSA-N Cc1nc(-c(c(C#N)c2)cc3c2N(C)CCC3)ccc1 Chemical compound Cc1nc(-c(c(C#N)c2)cc3c2N(C)CCC3)ccc1 MINYWMSCUCJKMH-UHFFFAOYSA-N 0.000 description 1
- FWBGXVWXBCQJRM-UHFFFAOYSA-N Cc1ncc(-c(c(C(F)F)c2)cc3c2N(C)CCC3)[s]1 Chemical compound Cc1ncc(-c(c(C(F)F)c2)cc3c2N(C)CCC3)[s]1 FWBGXVWXBCQJRM-UHFFFAOYSA-N 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2014092380 | 2014-11-27 | ||
| CNPCT/CN2014/092380 | 2014-11-27 | ||
| CNPCT/CN2015/092965 | 2015-10-27 | ||
| CN2015092965 | 2015-10-27 | ||
| PCT/US2015/062794 WO2016086200A1 (en) | 2014-11-27 | 2015-11-25 | 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017537100A JP2017537100A (ja) | 2017-12-14 |
| JP2017537100A5 true JP2017537100A5 (enExample) | 2019-01-10 |
| JP6771464B2 JP6771464B2 (ja) | 2020-10-21 |
Family
ID=55024234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017528520A Active JP6771464B2 (ja) | 2014-11-27 | 2015-11-25 | Ｃｂｐおよび／またはｅｐ３００インヒビターとしての、４，５，６，７−テトラヒドロ−１ｈ−ピラゾロ［４，３−ｃ］ピリジン−３−アミン化合物 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US9763922B2 (enExample) |
| EP (2) | EP3224258B1 (enExample) |
| JP (1) | JP6771464B2 (enExample) |
| CN (1) | CN107531690B (enExample) |
| WO (1) | WO2016086200A1 (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA40943A (fr) | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
| MA40940A (fr) * | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
| EP3218376B1 (en) | 2014-11-10 | 2019-12-25 | Genentech, Inc. | Bromodomain inhibitors and uses thereof |
| CN107223057A (zh) * | 2014-12-05 | 2017-09-29 | H·李·莫菲特癌症中心研究所公司 | 布罗莫结构域抑制剂作为癌症免疫治疗的补充剂 |
| JP6709792B2 (ja) | 2015-01-29 | 2020-06-17 | ジェネンテック， インコーポレイテッド | 治療用化合物およびその使用 |
| AR104259A1 (es) * | 2015-04-15 | 2017-07-05 | Celgene Quanticel Res Inc | Inhibidores de bromodominio |
| MA45122A (fr) * | 2016-05-24 | 2019-04-10 | Constellation Pharmaceuticals Inc | Inhibiteurs hétérocycliques de cbp/ep300 et leur utilisation dans le traitement du cancer |
| EP3464286B1 (en) | 2016-05-24 | 2021-08-18 | Genentech, Inc. | Pyrazolopyridine derivatives for the treatment of cancer |
| WO2018022637A1 (en) | 2016-07-25 | 2018-02-01 | Epizyme, Inc. | Crebbp related cancer therapy |
| GB201617627D0 (en) * | 2016-10-18 | 2016-11-30 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201617630D0 (en) * | 2016-10-18 | 2016-11-30 | Cellcentric Ltd | Pharmaceutical compounds |
| JP7300394B2 (ja) | 2017-01-17 | 2023-06-29 | ヘパリジェニックス ゲーエムベーハー | 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害 |
| US11274100B2 (en) | 2017-06-21 | 2022-03-15 | Daiichi Sankyo Company, Limited | EP300/CREBBP inhibitor |
| DK3681885T3 (da) | 2017-09-15 | 2024-04-15 | Forma Therapeutics Inc | Tetrahydro-imidazo-quinolinsammensætninger som cbp/p300-inhibitorer |
| MA50520A (fr) | 2017-11-02 | 2020-09-09 | Aicuris Gmbh & Co Kg | Nouveaux indole-2-carboxamides à substitution pyrazolo-pipéridine hautement actifs agissant contre le virus de l'hépatite b (vhb) |
| KR102815607B1 (ko) | 2018-03-29 | 2025-05-30 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 전사 활성화 단백질의 이미다조피페라진 억제제 |
| US10899769B2 (en) | 2018-04-06 | 2021-01-26 | Board Of Regents, The University Of Texas System | Imidazopiperazinone inhibitors of transcription activating proteins |
| GB201806320D0 (en) * | 2018-04-18 | 2018-05-30 | Cellcentric Ltd | Process |
| GB201809295D0 (en) | 2018-06-06 | 2018-07-25 | Institute Of Cancer Res Royal Cancer Hospital | Lox inhibitors |
| EP3587418B1 (en) * | 2018-06-29 | 2021-09-01 | Forma Therapeutics, Inc. | Inhibitors of creb binding protein (cbp) |
| AU2019295790B2 (en) * | 2018-06-29 | 2023-07-13 | Forma Therapeutics, Inc. | Inhibiting creb binding protein (CBP) |
| CN109187832B (zh) * | 2018-09-30 | 2021-07-30 | 华润三九医药股份有限公司 | Lc-ms/ms测定去氧肾上腺素浓度的方法及样品的前处理方法 |
| GB201818750D0 (en) | 2018-11-16 | 2019-01-02 | Institute Of Cancer Res Royal Cancer Hospital | Lox inhibitors |
| CN111320621B (zh) * | 2018-12-14 | 2022-10-04 | 中国科学院广州生物医药与健康研究院 | 一种吲嗪类化合物及其制备方法和应用 |
| ES2989353T3 (es) * | 2019-02-27 | 2024-11-26 | Constellation Pharmaceuticals Inc | Derivados de N-(piridinil)acetamida como inhibidores de HAT P300/CBP y métodos para su uso |
| EP3930759A4 (en) * | 2019-02-27 | 2023-03-22 | Cullgen (Shanghai), Inc. | CYCLIC AMP-RESPONSIVE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE |
| EP3937940A4 (en) | 2019-03-15 | 2022-12-21 | Forma Therapeutics, Inc. | Inhibiting cyclic amp-responsive element-binding protein (creb) |
| CN113784967B (zh) * | 2019-03-15 | 2024-07-26 | 福马治疗股份有限公司 | 用于治疗雄激素受体阳性形式的癌症的组合物和方法 |
| WO2020243519A1 (en) * | 2019-05-29 | 2020-12-03 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| CN110170052B (zh) * | 2019-06-21 | 2020-07-10 | 复旦大学 | Cbp-p300抑制剂在肠道损伤疾病中的应用 |
| TW202120095A (zh) * | 2019-08-05 | 2021-06-01 | 美商美國禮來大藥廠 | 7,8-二氫-4H-吡唑并[4,3-c]氮呯-6-酮化合物 |
| AU2020356575A1 (en) | 2019-09-27 | 2022-04-14 | Disc Medicine, Inc. | Methods for treating myelofibrosis and related conditions |
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| EP4140996A4 (en) * | 2020-04-25 | 2024-04-24 | Pharmablock Sciences (Nanjing), Inc. | CBP/EP300 INHIBITOR AND USE THEREOF |
| KR20230012539A (ko) | 2020-05-13 | 2023-01-26 | 디스크 메디슨, 인크. | 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체 |
| CN116507333B (zh) * | 2020-08-27 | 2025-05-09 | 上海睿跃生物科技有限公司 | 环amp反应元件结合蛋白(cbp)和/或300kda腺病毒e1a结合蛋白(p300)降解化合物和使用方法 |
| US11801243B2 (en) | 2020-09-23 | 2023-10-31 | Forma Therapeutics, Inc. | Bromodomain inhibitors for androgen receptor-driven cancers |
| US11795168B2 (en) | 2020-09-23 | 2023-10-24 | Forma Therapeutics, Inc. | Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP) |
| WO2022072648A1 (en) * | 2020-10-02 | 2022-04-07 | Board Of Regents, The University Of Texas System | Imidazopiperazine inhibitors of transcription activating proteins |
| CN116348112A (zh) * | 2020-10-02 | 2023-06-27 | 德州大学系统董事会 | 转录激活蛋白的咪唑并哌嗪抑制剂 |
| US20240122941A1 (en) * | 2020-12-25 | 2024-04-18 | National Cancer Center | Therapy based on synthetic lethality in swi/snf complex-dysfunction cancer |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| CN115340529A (zh) * | 2021-05-14 | 2022-11-15 | 武汉朗来科技发展有限公司 | 一种rock抑制剂的酸加成盐及盐的晶型、组合物和药物用途 |
| CR20240191A (es) | 2021-11-12 | 2024-09-13 | Insilico Medicine Ip Ltd | Inhibidores de molécula pequeña de proteasa 1 específica de ubiquitina (usp1) y usos de los mismos |
| CN117843618A (zh) * | 2022-08-29 | 2024-04-09 | 北京沐华生物科技有限责任公司 | 一种ep300/cbp调节剂及其制备方法和用途 |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
| WO2025001864A1 (en) * | 2023-06-30 | 2025-01-02 | Beijing Double-Crane Runchuang Technology Co., Ltd. | Fascin inhibitors |
| CN117069956B (zh) * | 2023-08-22 | 2025-04-08 | 南京科技职业学院 | 一种具有一维超分子结构的手性膦镍(ii)配合物及其制备方法和应用 |
| WO2025111184A1 (en) | 2023-11-21 | 2025-05-30 | Fmc Corporation | Substituted tetrahydroquinoline and tetrahydroquinoxaline herbicides |
| WO2025108411A1 (zh) * | 2023-11-24 | 2025-05-30 | 北京沐华生物科技有限责任公司 | 一种ep300/cbp调节剂及其制备方法和用途 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| EP0491007B1 (en) | 1989-09-08 | 1996-03-13 | The Johns Hopkins University | Structural alterations of the egf receptor gene in human gliomas |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| DE69428764T2 (de) | 1993-12-24 | 2002-06-20 | Merck Patent Gmbh | Immunokonjugate |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| HU216142B (hu) | 1994-07-21 | 1999-04-28 | Akzo Nobel N.V. | Ciklusos keton-peroxidokat tartalmazó kompozíciók, és azok alkalmazása (ko)polimerek módosítására |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| ES2332984T3 (es) | 1995-03-30 | 2010-02-16 | Pfizer Products Inc. | Derivados de quinazolinas. |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| EP0831880A4 (en) | 1995-06-07 | 2004-12-01 | Imclone Systems Inc | ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH |
| WO1997002266A1 (en) | 1995-07-06 | 1997-01-23 | Novartis Ag | Pyrrolopyrimidines and processes for the preparation thereof |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| CN1923818A (zh) | 1996-04-12 | 2007-03-07 | 沃尼尔·朗伯公司 | 酪氨酸激酶的不可逆抑制剂 |
| ATE227283T1 (de) | 1996-07-13 | 2002-11-15 | Glaxo Group Ltd | Kondensierte heterozyklische verbindungen als protein kinase inhibitoren |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| AU7165698A (en) | 1997-05-06 | 1998-11-27 | American Cyanamid Company | Use of quinazoline compounds for the treatment of polycystic kidney disease |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| BR9814116A (pt) | 1997-11-06 | 2000-10-03 | American Cyanamid Co | Uso de derivados de quinazolina como inibidores de cinase de tirosina para tratamento de pólipo colÈnico |
| BR9915487A (pt) | 1998-11-19 | 2001-07-31 | Warner Lambert Co | N-[4-(3-cloro-4-flúor-fenilamino) - 7 - (3-morfolin-4-il-propóxi)-quinazolin-6-il]-acrilamida, um inibidor irreversìvel de tirosina quinases |
| BR0312924A (pt) | 2002-07-25 | 2005-07-12 | Pharmacia Italia Spa | Biciclo-pirazóis ativos como inibidores de quinase, processo para sua preparação e composições farmacêuticas compreendendo os mesmos |
| JP2005537290A (ja) | 2002-07-25 | 2005-12-08 | ファルマシア・イタリア・エス・ピー・エー | キナーゼ阻害剤として活性なビシクロピラゾール類、その製造方法、およびそれを含有する薬学的組成物 |
| JP2006519816A (ja) | 2003-03-11 | 2006-08-31 | ファルマシア・イタリア・ソシエタ・ペル・アツィオーニ | キナーゼ阻害剤として活性なビシクロピラゾール誘導体、それらの製造方法、及びそれらを含んでなる医薬組成物 |
| AU2006244885B2 (en) | 2005-05-09 | 2011-03-31 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| AU2006265108C1 (en) | 2005-07-01 | 2013-01-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) |
| US7947686B2 (en) | 2005-12-12 | 2011-05-24 | Nerviano Medical Sciences S.R.L. | Substituted pyrazolo[4,3-c]pyridine derivatives active as kinase inhibitors |
| WO2007099166A1 (en) | 2006-03-03 | 2007-09-07 | Nerviano Medical Sciences S.R.L. | Pyrazolo-pyridine derivatives active as kinase inhibitors |
| US8476260B2 (en) | 2007-12-28 | 2013-07-02 | Mitsubishi Tanabe Pharma Corporation | Antitumor agent |
| EP2242773B1 (en) | 2008-02-11 | 2017-06-14 | Cure Tech Ltd. | Monoclonal antibodies for tumor treatment |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| AR071780A1 (es) | 2008-05-15 | 2010-07-14 | Nerviano Medical Sciences Srl | Derivados de carbamoilo de carbonilamino-pirazoles biciclicos como profarmacos |
| MX2011002250A (es) | 2008-08-25 | 2011-08-17 | Amplimmune Inc | Antagonistas de muerte celular programada-1 y métodos de uso de los mismos. |
| PT2376535T (pt) | 2008-12-09 | 2017-06-23 | Hoffmann La Roche | Anticorpos anti-pd-l1 e a sua utilização para a melhoria do funcionamento das células t |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| CN101812063B (zh) | 2010-03-18 | 2012-04-25 | 中国医学科学院医药生物技术研究所 | α-萘磺酰胺基五元杂环类化合物及其抑瘤活性 |
| WO2013097052A1 (en) * | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| WO2013148114A1 (en) * | 2012-03-30 | 2013-10-03 | University Of Florida Research Foundation, Inc. | P300/cbp inhibitors and methods of use |
| WO2014138727A1 (en) * | 2013-03-08 | 2014-09-12 | Board Of Regents, The University Of Texas System | Suppression of malignant mesothelioma by overexpression or stimulation of endothelial protein c receptors (epcr) |
-
2015
- 2015-11-25 US US14/952,821 patent/US9763922B2/en active Active
- 2015-11-25 EP EP15816578.7A patent/EP3224258B1/en active Active
- 2015-11-25 CN CN201580074597.7A patent/CN107531690B/zh active Active
- 2015-11-25 EP EP19191423.3A patent/EP3632915A1/en not_active Withdrawn
- 2015-11-25 WO PCT/US2015/062794 patent/WO2016086200A1/en not_active Ceased
- 2015-11-25 JP JP2017528520A patent/JP6771464B2/ja active Active
-
2017
- 2017-08-02 US US15/667,227 patent/US20170333406A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017537100A5 (enExample) | ||
| JP2017530176A5 (enExample) | ||
| JP2019516757A5 (enExample) | ||
| JP2019516759A5 (enExample) | ||
| JP2017526696A5 (enExample) | ||
| JP2017533250A5 (enExample) | ||
| JP2017525740A5 (enExample) | ||
| JP2017533249A5 (enExample) | ||
| JP6835472B2 (ja) | 癌の処置のための組成物 | |
| AU2017200269B2 (en) | Methods of using c-Met modulators | |
| JP2018501287A5 (enExample) | ||
| CN102985403B (zh) | 具有抗雄激素性质的新型芳基酰胺衍生物 | |
| JP2016529312A5 (enExample) | ||
| Li et al. | Discovery of novel quinazolines as potential anti-tubulin agents occupying three zones of colchicine domain | |
| ZA200307665B (en) | Combination comprising N-{5-[4-(4-methyl-piperazinomethyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and a chemotherapeutic agent. | |
| JP2018507191A5 (enExample) | ||
| KR20140025433A (ko) | Ａｋｔ 억제제 화합물 및 베무라페닙의 조합물, 및 사용 방법 | |
| JP2014506601A5 (enExample) | ||
| RU2020131507A (ru) | Имидазопиперазиновые ингибиторы белков-активаторов транскрипции | |
| US20220160672A1 (en) | Pharmaceutical compositions for modulating a kinase cascade and methods of use thereof | |
| JP2019529444A5 (enExample) | ||
| JP2011521938A5 (enExample) | ||
| CN109843872A (zh) | 作为ido抑制剂和/或ido-hdac双重抑制剂的多环化合物 | |
| CA2604907A1 (en) | Combination cancer therapy with bis(thiohydrazide) amide compounds | |
| TW201016671A (en) | Novel imidazolidine compounds as androgen receptor modulators |